<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04725669</url>
  </required_header>
  <id_info>
    <org_study_id>UHID-06</org_study_id>
    <nct_id>NCT04725669</nct_id>
  </id_info>
  <brief_title>Seroprevalence of Pertussis Among Children and Adolescents in Croatia</brief_title>
  <official_title>Seroprevalence of Pertussis Antibodies Among Children and Adolescents in Croatia - Investigation of the Waning Vaccine-induced Immunity in Children and Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital for Infectious Diseases, Croatia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital for Infectious Diseases, Croatia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pertussis is a vaccine preventable disease caused by Bordetella pertussis. Older children and&#xD;
      adolescents with pertussis continue to be a significant source of infection for incompletely&#xD;
      vaccinated infants who are in harm for developing severe disease. The primary objective of&#xD;
      our study is to estimate the duration of protection elicited by the current vaccination&#xD;
      schedule against pertussis in Croatia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 15, 2021</start_date>
  <completion_date type="Anticipated">September 8, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 14, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Waning of vaccine-induced immunity</measure>
    <time_frame>1 day</time_frame>
    <description>Number of Participants In Each Specific Age Group With Negative Pertussis Toxin IgG Antibody Titre Measured by ELISA IgG Testkit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Seroprevalence</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Prevalence of Pertussis Toxin IgG Antibody Titre At Each Specific Age Subgroup</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Immunogenicity, Vaccine</condition>
  <arm_group>
    <arm_group_label>Seroprevalence of pertussis among children and adolescents in Croatia</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>For all patients participating in the study one serum sample will be collected for serological analysis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>ELISA IgG Testkit</intervention_name>
    <description>All samples will be tested for IgG antibody level to pertussis toxin using a commercial Bordetella pertussis ELISA IgG Testkit in accordance to the manufacturers' protocol in the laboratory at the University Hospital for Infectious Diseases in Zagreb.</description>
    <arm_group_label>Seroprevalence of pertussis among children and adolescents in Croatia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  children and adolescents from 6 to 18 years of age treated through Emergency room&#xD;
             and/or Day hospital of Pediatric Infectious Diseases Department at UHID;&#xD;
&#xD;
          -  appropriate vaccination with pertussis component containing vaccine by date and at the&#xD;
             appropriate time, according to Croatian NIP proven by insight in the Vaccination&#xD;
             Record Card&#xD;
&#xD;
          -  written informed consent obtained from the subject's parent or caregiver, as well as&#xD;
             from participants ≥ 16 years old.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  children under 6 years&#xD;
&#xD;
          -  children and adolescents with acute respiratory symptoms&#xD;
&#xD;
          -  children and adolescents with pertussis-like illness within 12 months&#xD;
&#xD;
          -  children and adolescents with unknown, uncompleted or irregular vaccination record&#xD;
&#xD;
          -  inpatients&#xD;
&#xD;
          -  children and adolescents with immunodeficiencies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Goran Tešović</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital for Infectious Diseases &quot;Dr Fran Mihaljević&quot;</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Goran Tešović</last_name>
    <phone>+385914012605</phone>
    <email>gtesovic@bfm.hr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vedran Stevanović</last_name>
    <phone>+385914012787</phone>
    <email>vstevanovic@bfm.hr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital for Infectious Diseases &quot;Dr Fran Mihaljević&quot;</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Goran Tešović</last_name>
      <phone>+385914012605</phone>
      <email>gtesovic@bfm.hr</email>
    </contact>
    <investigator>
      <last_name>Vedran Stevanović</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Croatia</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 20, 2021</study_first_submitted>
  <study_first_submitted_qc>January 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2021</study_first_posted>
  <last_update_submitted>February 10, 2021</last_update_submitted>
  <last_update_submitted_qc>February 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Whooping Cough</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

